Company intelligence / Profile preview

Hexagon Bio

Menlo Park, California, United Stateshexagonbio.com ↗

Ownership: Private
Employees: ~82
Development stage: Preclinical

Overview

Hexagon Bio is developing novel ADC payloads with mechanisms orthogonal to existing payload mechanisms for treating cancer patients with unmet needs. The company is advancing candidates toward development nomination.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculesAntibody Drug Conjugate (ADC) payloads
Industry: Biotech

Drug pipeline

6 assets

ADC 3

Approved

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Hexagon Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hexagon Bio.

Explore the full profile